Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature

In patients with renal failure and hemodialysis, there are difficulties in drug selection and dose adjustment for cancer treatment. The use of immune checkpoint inhibitors (ICIs), including pembrolizumab, approved by the U.S. Food and Drug Administration (FDA) for patients with metastatic non-small...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Jae Won, Kwon, Jung, Lim, Taekyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967386/
https://www.ncbi.nlm.nih.gov/pubmed/36837526
http://dx.doi.org/10.3390/medicina59020325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967386/
https://www.ncbi.nlm.nih.gov/pubmed/36837526
http://dx.doi.org/10.3390/medicina59020325

Ejemplares similares